What is Zubsolv and What are its Effects?
Zubsolv is intended for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.
Since Zubsolv is intended for maintenance treatment, the dosage should be progressively adjusted in increments/decrements of 1.4 mg/0.36 mg or 2.8 mg/0.72 mg to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms.
Zubsolv may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery, especially during treatment induction and dose adjustment. Patients should be cautioned about driving or operating hazardous machinery until they are reasonably certain that Zubsolv therapy does not adversely affect his or her ability to engage in such activities.
- Used to assist in opioid dependence
- Not intented for long-term use
- White tablets in a triangular shape for the lower dosage strength (1.4 mg /0.36 mg)
- White tablets in a round shape for the higher dosage strength (5.7 mg/1.4 mg)
- Both tablets are debossed with the respective dosage strength
Due to the fact that Zubsolv has just been approved for use, no street names or nicknames have yet to appear.
Routes of Administration
Zobsolv is intended for sublingual administration in two dosage strengths, 1.4 mg and 5.7 mg. Each sublingual tablet also contains mannitol, citric acid, sodium citrate, microcrystalline cellulose, croscarmellose sodium, sucralose, menthol, silicon dioxide and sodium stearyl fumarate and menthol flavor.
Adverse Health Effects
- Increased sweating
- Extreme drowsiness
- Loss of coordination, weakness or limp feeling
- Blurred vision, slurred speech, thinking problems
- Redness, pain, or mouth numbness
- Loss of appetite
- Swelling of the lower limbs